Current Bare-Metal Stents: Similar to DES in the Very Long-Term

The largest randomized trial in history found no difference in the primary endpoint of death and nonfatal infarction between current conventional stents and drug-eluting stents at over 5 years in patients with stable or unstable coronary disease. As expected, NORSTENT did find a difference in revascularization rates between both groups.   This study presented at the<a href="https://solaci.org/en/2016/09/07/current-bare-metal-stents-similar-to-des-in-the-very-long-term/" title="Read more" >...</a>

A Study on Valve Thrombosis After TAVI

This study, presented in Rome at the European Society of Cardiology Congress 2016 and published simultaneously online in the Journal of the American College of Cardiology (JACC), has identified a post-TAVI valve thrombosis rate of 7% using multidetector computerized tomography (CT). However, the vast majority of cases were completely asymptomatic.   Previous studies had shown<a href="https://solaci.org/en/2016/09/07/a-study-on-valve-thrombosis-after-tavi/" title="Read more" >...</a>

Optimal Duration of DAPT: How to Predict Long-Term Events

Courtesy of Dr. Santiago F. Coroleu.   Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after percutaneous coronary intervention (PCI) reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB). However, the lack of information to accurately predict the occurrence of each event in out-of-hospital patients under<a href="https://solaci.org/en/2016/08/17/optimal-duration-of-dapt-how-to-predict-long-term-events/" title="Read more" >...</a>

DES in primary PCI: The Best Option?

Courtesy of Dr. Brian Nazareth Donato.   The relative safety of drug-eluting stents (DES) and conventional bare-metal stents (BMS) in primary angioplasty (percutaneous coronary intervention, PCI) in patients with ST elevation myocardial infarction (STEMI) is still subject of debate.   A search was carried out using Medline, CENTRAL, EMBASE, TCTMD and Cardiosource. There were 9673 patients included,<a href="https://solaci.org/en/2016/08/10/des-in-primary-pci-the-best-option/" title="Read more" >...</a>

DAPT after PCI with EES: 6 or 12 Months?

Original Title: 6-Month versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation. The IVUS-XPL Randomized Clinical Trial. Reference: Hong et al. JACC Cardiovasc Interv. 2016 May 11. [Epub ahead of print]   Courtesy of Dr. Brian Nazareth Donato.   This publication stems from the IVUS-XPL published by JAMA in November 2015. This study presents outcomes on the<a href="https://solaci.org/en/2016/07/25/dapt-after-pci-with-ees-6-or-12-months/" title="Read more" >...</a>

stent liberador de drogas protusion de placa

Tissue Protrusion after DES: Adverse Events at Long Term?

Original Title: Tissue Protrusion after Stent Implantation. An ADAPT-DES Intravascular Ultrasound Substudy. Reference: Fuyu Qiu et al. J Am Coll Cardiol Intv. 2016;9(14):1499-1507.   After DES implantation we may observe tissue protrusion (plaque or thrombus) relatively often, especially in unstable lesions; however, its clinical impact has not been studied. The aim of this study was<a href="https://solaci.org/en/2016/07/21/tissue-protrusion-after-des-adverse-events-at-long-term/" title="Read more" >...</a>

High bleeding risk: is BMS still justifiable?

Original Title: Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention? A Pre-Specified Analysis From the ZEUS Trial. Reference: Sara Ariotti et al. J Am Coll Cardiol Intv. 2016;9(5):426-436.   This work studied ischemic and bleeding events in high bleeding risk patients randomized to the zotarolimus eluting stent (ZEZ) Endeavor<a href="https://solaci.org/en/2016/03/15/high-bleeding-risk-is-bms-still-justifiable/" title="Read more" >...</a>

Triple Antithrombotic Scheme in AMI Patients undergoing PCI

Original Title: Outcomes of Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy, a Comparison of Clopidogrel vs. Prasugrel from the TRANSLATE-ACS Study. Reference: Jackson L.R. et al. JACC Cardiovasc Interv. 2015 Dec 21;8(14):1880-9. Courtesy of Dr Agustín Vecchia. In these last years, new and more powerful antiaggregants have<a href="https://solaci.org/en/2016/01/29/triple-antithrombotic-scheme-in-ami-patients-undergoing-pci/" title="Read more" >...</a>

DAPT TRIAL: double antiaggregation remains controversial

Article This multicenter randomized control study with placebo was designed to determine the risks and benefits of double antiaggregation for longer than 12 months post DES stenting. 9961 patients were randomized to continue on placebo or thienopyridine after 12 months. Thienopyridine reduces the incidence of in-stent thrombosis (0.4% vs 1.4%; p<0,001) and cardiovascular events (4.3%<a href="https://solaci.org/en/2015/06/24/dapt-trial-double-antiaggregation-remains-controversial/" title="Read more" >...</a>

ISAR-SAFE: 6 vs. 12 month clopidogrel administration after DES implantation

The aim of this randomized double blind control trial was to validate the safety and efficacy of 6 months vs. 12 months clopidogrel treatment in patients receiving DES. Primary end point was a combination of death, infarction, in-stent thrombosis, stroke and major bleeding. Secondary end point was the individual analysis of each one of the<a href="https://solaci.org/en/2015/06/24/isar-safe-6-vs-12-month-clopidogrel-administration-after-des-implantation/" title="Read more" >...</a>

dual antiplatelet therapy